Overview

A Study of Multiple Ascending Doses MY008211A in Healthy Adults

Status:
Active, not recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, double-blind, placebo-controlled, dose-escalation, and multiple-dose study to evaluate safety, tolerability, PK and PD of MY008211A Tablets in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Wuhan Createrna Science and Technology Co., Ltd